Novavax and Alnylam are in the spotlight following drug approval and regulatory updates, respectively.
Athira’s experimental drug fosgonimeton failed to slow cognitive decline. The biotech firm says it’s not giving up.
Athira's phase II/III LIFT-AD study on fosgonimeton for treating mild-to-moderate Alzheimer's disease fails to meet primary and secondary endpoints.